• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Whitehawk Therapeutics to Present at the Jefferies 2025 Global Healthcare Conference

    5/28/25 8:00:00 AM ET
    $WHWK
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $WHWK alert in real time by email

    MORRISTOWN, N.J., May 28, 2025 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (NASDAQ:WHWK), an oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved ADC cancer treatments, announced today its presentation at the Jefferies 2025 Global Healthcare Conference, taking place June 3-5, 2025, in New York City, NY. Dave Lennon, PhD, President and CEO, will present a company overview on Wednesday, June 4, 2025, from 2:00-2:30 PM ET.

    A live webcast of the fireside chat can be accessed by visiting the Whitehawk Therapeutics IR website and will be available for replay for approximately 30 days following the event.

    About Whitehawk Therapeutics

    Whitehawk Therapeutics is an oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved cancer treatments. Whitehawk's advanced three-asset ADC portfolio is engineered to overcome the limitations of first-generation predecessors to deliver a meaningful impact for patients with difficult-to-treat cancers. These assets are in-licensed from WuXi Biologics under an exclusive development and global commercialization agreement. More information on the Company is available at www.whitehawktx.com and connect with us on LinkedIn.

    Contact:

    [email protected]

    Whitehawk Therapeutics, Inc. logo (PRNewsfoto/Whitehawk Therapeutics, Inc.)

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/whitehawk-therapeutics-to-present-at-the-jefferies-2025-global-healthcare-conference-302466333.html

    SOURCE Whitehawk Therapeutics, Inc.

    Get the next $WHWK alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $WHWK

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $WHWK
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Tempus Announces Collaboration with Whitehawk Therapeutics to Advance Biomarker-Driven Oncology Research

    Tempus AI, Inc. (NASDAQ:TEM), a technology company leading the adoption of AI to advance precision medicine, today announced a multi-year collaboration with Whitehawk Therapeutics, Inc. (NASDAQ:WHWK), an oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved antibody drug conjugates (ADC) cancer treatments. The collaboration aims to leverage Tempus' proprietary real-world dataset to advance biomarker-driven research and support the development of Whitehawk Therapeutics' oncology pipeline. Under the agreement, Whitehawk Therapeutics will apply Tempus' de-identified multimodal database to support the biotech's clinical trial

    10/16/25 8:30:00 AM ET
    $TEM
    $WHWK
    Computer Software: Programming Data Processing
    Technology
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Whitehawk Therapeutics to Participate in Upcoming Investor Conferences

    MORRISTOWN, N.J., Sept. 2, 2025 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (NASDAQ:WHWK), an oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved ADC cancer treatments, announced today that the Company's president and CEO, Dave Lennon, PhD, will participate in a fireside chat during the following upcoming investor conferences in New York City, NY: Morgan Stanley 23rd Annual Global Healthcare Conference on Monday, September 8, 2025. Fireside chat at 4:50 PM ET.H.C. Wainwright 27th Annual Global Investment Conference on Tuesday, September 9, 2025. Fireside chat at 3:30 PM ET.A live webcast of the fireside chat events can be

    9/2/25 8:00:00 AM ET
    $WHWK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Whitehawk Therapeutics Reports Second Quarter 2025 Financial Results and Recent Highlights

    MORRISTOWN, N.J., Aug. 7, 2025 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (NASDAQ:WHWK), an oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved ADC cancer treatments, today announced financial results for the second quarter ended June 30, 2025, and provided recent corporate progress. "We're pleased with the progress made in Q2 to advance our ADC portfolio and remain on track to file INDs for our first two programs – HWK-007 and HWK-016 – by year-end 2025, with the third program, HWK-206, to follow in mid-2026," said Dave Lennon, PhD, President and CEO of Whitehawk Therapeutics. "We believe we are well-positioned to advan

    8/7/25 8:00:00 AM ET
    $WHWK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $WHWK
    SEC Filings

    View All

    SEC Form 10-Q filed by Whitehawk Therapeutics Inc.

    10-Q - Whitehawk Therapeutics, Inc. (0001422142) (Filer)

    8/7/25 4:25:08 PM ET
    $WHWK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Whitehawk Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Whitehawk Therapeutics, Inc. (0001422142) (Filer)

    8/7/25 8:03:57 AM ET
    $WHWK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 8-K filed by Whitehawk Therapeutics Inc.

    8-K - Whitehawk Therapeutics, Inc. (0001422142) (Filer)

    6/13/25 4:39:10 PM ET
    $WHWK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $WHWK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Zhao Baiteng

    4 - Whitehawk Therapeutics, Inc. (0001422142) (Issuer)

    6/17/25 8:10:46 PM ET
    $WHWK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Desai Neil

    4 - Whitehawk Therapeutics, Inc. (0001422142) (Issuer)

    6/17/25 4:37:32 PM ET
    $WHWK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Hirmand Mohammad

    4 - Whitehawk Therapeutics, Inc. (0001422142) (Issuer)

    6/16/25 4:58:37 PM ET
    $WHWK
    Biotechnology: Pharmaceutical Preparations
    Health Care